ArticleMedicine2026
Association between oxidative balance score and metabolic dysfunction-associated steatotic liver disease in US adolescents: A cross-sectional NHANES analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a growing public health concern among obese youth. Oxidative stress plays a central role in the pathogenesis of MASLD, and an aggregate oxidative balance score (OBS), reflecting the balance between antioxidant and pro-oxidant exposures, may serve as a predictor of disease risk. The present study examined the association between OBS and MASLD among adolescents in the United States (US). We conducted a cross-sectional analysis of 2203 adolescents aged 12 to 17 years using data from the National Health and Nutrition Examination Survey 2017 to 2023. A US Fatty Liver Index score ≥ 30 was used as the diagnostic benchmark for MASLD classification. Logistic regression models were applied to quantify the association between OBS and MASLD, restricted cubic spline analyses were used to assess nonlinearity, and stratified analyses were performed according to sex, survey cycle, ethnicity, poverty-income ratio, age, height, and weight. The median OBS was 12.0, with an interquartile range of 3 to 18. MASLD was identified in 298 participants, corresponding to an unweighted sample prevalence of 13.53%. The adjusted association between OBS and MASLD showed evidence of nonlinearity. In an exploratory piecewise model, the data-derived turning point was 19.8; above this value, each 1-point increase in OBS was associated with 8% lower odds of MASLD, while the association below this value was not statistically significant. Subgroup estimates were generally inverse but imprecise. Among adolescents in the analytical sample, higher OBS was associated with lower MASLD prevalence after adjustment for age, sex, and ethnicity. The nonlinear pattern and data-derived turning point are exploratory and should not be interpreted as a clinical cutoff. Given the cross-sectional design and surrogate US Fatty Liver Index definition, these findings are hypothesis-generating and require confirmation in longitudinal studies using direct liver assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.